DD202-114是一种高效、选择性的GLP1R激动剂。它能够促进cAMP积累，降低血糖水平和食物摄入量，并展现出对hERG通道的抑制作用以及强效的CYP2C8抑制活性。因此，DD202-114在2型糖尿病和肥胖症的研究中具有潜在应用价值。

/

-25~-15℃避光保存，有效期3年。

[1] Zhang Z，Pan H，Guo L，Cai C，Chen T，Zhang Z，Yang X，Zheng H，Jiang C，Wang Z，Yang Y，Wang Z，Zhang X，Zhang Y，Liu D,Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor,J Med Chem,2024 Sep 12;67(17):14820-14839,doi: 10.1021/acs.jmedchem.4c01177,Epub 2024 Aug 14,PMID: 39140772.[2]Dong G，Ye Q，Li W，Zhang S，Yang Z，Zhang R，Deng T，Li H，Zhang Y，Zhang X，He S，Zhou D，Zhang J，He P，Yu Z，Li Y,Discovery and Evaluation of DA-302168S as an Efficacious Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist,J Med Chem,2025 May 8;68(9):9555-9583,doi: 10.1021/acs.jmedchem.5c00242,Epub 2025 Apr 21,PMID: 40257122.